{"entity":{"id":"escort-1st","kind":"trial","name":"ESCORT-1st","aka":[],"tldr":"ESCORT-1st is China's first-line immunotherapy trial for squamous oesophageal cancer, one of five that together made chemo-immunotherapy the global standard.","summary":"ESCORT-1st, trial NCT03691090 sponsored by Jiangsu Hengrui and published in JAMA in 2021, is China's first-line immunotherapy trial for advanced oesophageal squamous cell carcinoma, one of five concordant trials that together made chemo-immunotherapy the global standard. It randomised 596 patients to camrelizumab or placebo with paclitaxel and cisplatin and met its primary overall survival endpoint, confirmed at the final analysis in 2024; camrelizumab is approved in China for the disease but not in the United States, and the later ESCORT-NEO trial showed neoadjuvant camrelizumab plus chemotherapy raises pathologic complete response in resectable disease. OnCo links it to oesophageal cancer, PD-1 as a target, camrelizumab, Jing Huang and Rui-Hua Xu. Whether Chinese PD-1 antibodies reach patients outside China for this indication is the open question.","status":"positive","asOf":"2026-09-07","links":[{"label":"ClinicalTrials.gov NCT03691090","url":"https://clinicaltrials.gov/study/NCT03691090"},{"label":"JAMA 2021","url":"https://jamanetwork.com/journals/jama/fullarticle/2784143"}],"tags":[],"related":[],"cancers":["esophageal"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":["pd1"],"drugs":["camrelizumab"],"companies":["hengrui"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["huang-jing-cams","xu-rui-hua"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT03691090","phase":"3","setting":"First-line advanced oesophageal squamous cell carcinoma (China): camrelizumab + paclitaxel/cisplatin vs placebo + chemotherapy","sponsor":"Jiangsu Hengrui","result":"OS 15.3 vs 12.0 months, HR 0.70.","started":"2018-12-03","startedType":"actual","yearReported":2021,"enrolled":596,"enrolledBasis":"registry","outcomes":[{"endpoint":"Overall survival","primary":true,"unit":"months","arms":[{"name":"Camrelizumab + chemotherapy","n":298,"value":15.3},{"name":"Placebo + chemotherapy","n":298,"value":12}],"hr":0.7,"source":"https://jamanetwork.com/journals/jama/fullarticle/2784143"}],"replication":"One of five concordant first-line ESCC chemo-IO trials."},"route":"/trials/escort-1st/","neighbours":{"cancer":[{"id":"esophageal","kind":"cancer","name":"Oesophageal cancer","route":"/cancers/esophageal/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"target":[{"id":"pd1","kind":"target","name":"PD-1","route":"/targets/pd1/"}],"drug":[{"id":"camrelizumab","kind":"drug","name":"Camrelizumab","route":"/drugs/camrelizumab/"}],"company":[{"id":"hengrui","kind":"company","name":"Jiangsu Hengrui Pharmaceuticals","route":"/companies/hengrui/"}],"person":[{"id":"huang-jing-cams","kind":"person","name":"Jing Huang","route":"/people/huang-jing-cams/"},{"id":"xu-rui-hua","kind":"person","name":"Rui-Hua Xu","route":"/people/xu-rui-hua/"}]}}